2Wendt TM,Tanji N,Guo J,et al.RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy[J].Am J Pathol,2003,162(4):1123-1137.
3Tuttle KR.Linking metabolism and immunology:Diabetic nephr-opathy is an Inflammatory disease[J].J Am Soc Nephrol,2005,16(6):1537-1538.
4Mora C,Navarro JF.Inflammation and diabetic nephrop athy[J].Curr Diab Rep,2006,6(6):463-468.
5Ruggenenti P,Perticucci E.Role of remission clinics in the longitu dinai treatment of CKD[J].J American Society of Nephrology,2008,19(6):1213-1224.
5KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
6Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
7Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
8Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
9Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
10Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
